ARPE-19-derived VEGF-containing exosomes promote neovascularization in HUVEC: the role of the melanocortin receptor 5.
Cell Line
Cell Survival
/ drug effects
Culture Media
/ chemistry
Cytochrome P-450 CYP2E1
/ metabolism
Exosomes
/ metabolism
Glucose
/ metabolism
Human Umbilical Vein Endothelial Cells
/ metabolism
Humans
Imidazoles
/ pharmacology
NF-kappa B
/ metabolism
Neovascularization, Physiologic
/ drug effects
Peptides, Cyclic
/ pharmacology
Reactive Oxygen Species
/ metabolism
Receptor, Melanocortin, Type 1
/ agonists
Receptor, Melanocortin, Type 3
/ agonists
Receptors, Melanocortin
/ agonists
Retinal Pigment Epithelium
/ metabolism
Signal Transduction
/ drug effects
Vascular Endothelial Growth Factor A
/ metabolism
alpha-MSH
/ analogs & derivatives
Diabetes
exosomes
melanocortin receptors
oxidative stress
vasculogenesis
Journal
Cell cycle (Georgetown, Tex.)
ISSN: 1551-4005
Titre abrégé: Cell Cycle
Pays: United States
ID NLM: 101137841
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
12
2
2019
medline:
6
5
2020
entrez:
12
2
2019
Statut:
ppublish
Résumé
ARPE-19 retinal pigment epithelial cells cultured in a medium containing 35 mM D-glucose led to an augmented ROS formation and release of vascular endothelial factor (VEGF)-containing exosomes compared to ARPE-19 cells cultured in a medium containing 5 mM D-glucose (standard medium). Exposing these cells to the melanocortin 5 receptor agonist (MCR
Identifiants
pubmed: 30739530
doi: 10.1080/15384101.2019.1568745
pmc: PMC6422460
doi:
Substances chimiques
BMS-470539
0
Culture Media
0
Imidazoles
0
MC1R protein, human
0
MC3R protein, human
0
NF-kappa B
0
PG 901
0
Peptides, Cyclic
0
Reactive Oxygen Species
0
Receptor, Melanocortin, Type 1
0
Receptor, Melanocortin, Type 3
0
Receptors, Melanocortin
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
acetyl-norleucyl(4)-(aspartyl(5)-histidyl(6)-phenylalanyl(7)-arginyl(8)-tryptophyl(9)-lysyl(10))cyclo-alpha-MSH(4-10)amide
0
melanocortin 5 receptor
0
alpha-MSH
581-05-5
Cytochrome P-450 CYP2E1
EC 1.14.13.-
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
413-424Références
Immunol Lett. 2006 Nov 15;107(2):102-8
pubmed: 17067686
Biochem Pharmacol. 2013 Dec 1;86(11):1603-13
pubmed: 24076420
Folia Med Cracov. 2015;55(4):35-48
pubmed: 26867118
Oxid Med Cell Longev. 2016;2016:3164734
pubmed: 26881021
J Med Chem. 2008 May 8;51(9):2701-7
pubmed: 18412316
Int J Cancer. 2005 Feb 20;113(5):752-60
pubmed: 15499615
Mol Aspects Med. 2012 Aug;33(4):376-98
pubmed: 22575354
Int J Biochem Cell Biol. 2018 Jun;99:236-256
pubmed: 29654900
Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34
pubmed: 11033038
Neuroreport. 2006 Feb 27;17(3):287-91
pubmed: 16462599
Best Pract Res Clin Endocrinol Metab. 2018 Apr;32(2):93-106
pubmed: 29678289
J Cell Mol Med. 2016 Aug;20(8):1457-66
pubmed: 26999719
Mol Metab. 2016 Aug 05;5(10):807-822
pubmed: 27688995
Surv Ophthalmol. 2016 Mar-Apr;61(2):187-96
pubmed: 26074354
Curr Drug Metab. 2009 Feb;10(2):164-78
pubmed: 19275551
J Cell Mol Med. 2013 Nov;17(11):1475-83
pubmed: 24118735
Mol Cell Proteomics. 2010 Jun;9(6):1085-99
pubmed: 20124223
J Burn Care Res. 2010 Jan-Feb;31(1):158-75
pubmed: 20061852
Obesity (Silver Spring). 2008 Sep;16(9):2113-9
pubmed: 18551113
J Biol Chem. 2001 Mar 30;276(13):9910-6
pubmed: 11133993
Crit Rev Immunol. 2005;25(3):215-23
pubmed: 16048436
Biochem Biophys Res Commun. 2002 Apr 12;292(4):1075-80
pubmed: 11944925
Oxid Med Cell Longev. 2017;2017:1420892
pubmed: 29158871
Immunology. 2001 Feb;102(2):165-72
pubmed: 11260321
Pharmacol Rev. 2012 Jul;64(3):676-705
pubmed: 22722893
Exp Cell Res. 2013 Aug 1;319(13):2113-23
pubmed: 23669273
J Mol Endocrinol. 2010 Apr;44(4):237-46
pubmed: 20110403
Cell Tissue Res. 2016 Sep;365(3):621-41
pubmed: 27289232
J Cell Mol Med. 2017 May;21(5):968-974
pubmed: 27998021
Int J Mol Sci. 2018 Jul 20;19(7):
pubmed: 30037017
Mol Vis. 1999 Nov 03;5:32
pubmed: 10562656
Physiol Rev. 2005 Jul;85(3):845-81
pubmed: 15987797
Mediators Inflamm. 2016;2016:7368389
pubmed: 26949291
Oncotarget. 2017 Jul 18;8(29):47642-47654
pubmed: 28514752